Abuse liability study results of lisdexamfetamine dimesylate (NRP104) presented at CPDD
... New River Pharmaceuticals Inc. (NASDAQ: NRPH) designed lisdexamfetamine dimesylate as an inacti...NRP104 significantly reduced symptoms of attention deficit hyperactivity disorder in children
TorontoV Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) and New River Pharmaceuticals Inc. (Nasdaq: NRPH) announced today that treatment with the investigational drug, lisdexamfetamine dimesylate (NRP104), demonstrated statistically significant reduction in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years according to the results of a phase III trial p...